

83.4. Leukemia: Chronic Myeloid Leukemia

Authors

Jerald P. Radich, Soheil Meshinchi, Elihu H. Estey, William L. Carroll, Ryan Cassaday, Steven Coutre, Elaine S. Jaffe, John P. Leonard

Emerging Prognostic Factors for Clinical Care

The authors have not noted any emerging prognostic factors for clinical care at this time.

Risk Assessment Models

All therapies (TKI, transplantation) are more effective in CP than advanced-phase (AP, BC) CML. Thus, the staging of CML phase by blast count and morphology is the primary risk stratification measure. Other clinical systems (Sokal, Hasford, Euro) are helpful in accessing risk and thus in choosing a TKI (e.g., a CP patient with a high risk score might be better served by a more potent second generation TKI).

Recommendations for Clinical Trial Stratification

The authors have not provided any recommendations for clinical trial stratification at this time.

Bibliography